Project Grant R01HL175488

Award Date 7/1/24
Completion Date 6/30/28
Dollars Obligated $2.2M
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
New York, NY 10029, USA
Similar Awards
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $711,039 to the Research Institute at Nationwide Children's Hospital to investigate the role of cardiac m6A methyltransferases in the pathogenesis of fetal dilated cardiomyopathy (DCM). The project aims to determine the functions of the methyltransferases METTL3 and METTL14 in embryonic mouse myocardium, and whether their loss...
This $154,568 Project Grant awarded by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) supports research to investigate the role of extracellular matrix (ECM) in Down syndrome-associated congenital heart defects. The research, to be conducted at the Massachusetts Institute of Technology (MIT), aims to test the hypothesis that disruption of ECM during heart development leads to downstream effects on cell signaling,...
This Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (CFDA 93.847 - Diabetes, Digestive, and Kidney Diseases Extramural Research) provides $120,375 to Childrens Hospital Medical Center in Cincinnati, Ohio to develop advanced mouse models for studying the pathogenesis of myelodysplastic syndromes (MDS) caused by DDX41 gene mutations. The project aims to create genetic mouse models that accurately reflect the natural progression of DDX41-mutated MDS,...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) will support research to identify new therapeutic targets for dilated cardiomyopathy (DCM), a leading cause of heart failure. The $248,999 award to the University of California, San Diego aims to study the role of microRNAs in regulating sarcomeric and contractile functions in DCM, with the goal of developing mechanism-based therapeutic...
The federal Project Grant award R01HL171282, provided by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), supports research aimed at optimizing gene therapy for respiratory insufficiency in Duchenne muscular dystrophy (DMD). The $610,819 award to Duke University will fund a 4-year project to comprehensively examine the impact of dystrophin deficiency on respiratory function and neuropathology in humanized mouse models of DMD....
The federal Project Grant award R03HD113887, provided by the National Institute of Child Health and Human Development (NICHD) under the Child Health and Human Development Extramural Research program (CFDA 93.865), supports research to investigate the role of the ZFHX4 gene in lung mesenchyme development and its potential implications for understanding the pathogenesis of lung hypoplasia in congenital diaphragmatic hernia (CDH). The $164,990 award, with a performance period from August 1, 2024 to...
This Project Grant award, funded by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), supports research to investigate the role of the RNA-binding protein RBPMS in regulating cardiac function and disease. The $100,480 award, effective July 15, 2024 through June 30, 2026, will enable the principal investigator to characterize how RBPMS modulates RNA splicing to impact cardiomyocyte contraction, explore the functional...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $100,480 to The University of Texas Southwestern Medical Center to conduct research on understanding the roles of nuclear envelope proteins and DNA damage in cardiomyopathy. The key objectives of this 2-year research project are to: 1) characterize the DNA damage and DNA damage response in cardiomyocytes carrying LEMD2 mutations...
This $506,984 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), aims to investigate the role of the LRP1 gene in the development of congenital heart disease (CHD). The primary objectives are to: Examine the deployment and migration of cardiac neural crest cells (CNCCs) and their dependence on LRP1 using in vitro and in vivo cell lineage fate mapping analysis. Investigate the cellular and molecular...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $2,096,171 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to Rutgers, The State University of New Jersey, to study the role of connexin-43 (Cx43) in Duchenne muscular dystrophy (DMD)-associated cardiomyopathy. The grant aims to investigate how dystrophic microtubules link the lack of dystrophin to Cx43 remodeling, and whether phospho-Cx43 can correct the dystrophic microtubule and suppress Cx43...

ROLE OF RNA-BINDING PROTEIN DDX3X IN HEART DEVELOPMENT AND DISEASE - PROJECT SUMMARY THE RELATIVELY FINITE NUMBER OF ~20,000 PROTEIN CODING GENES IN THE MAMMALIAN GENOME LIMITS THE OVERALL DIVERSITY THAT TRANSCRIPTIONAL REGULATION CAN ACHIEVE IN A GIVEN BIOLOGICAL CONTEXT. THIS DIVERSITY CAN BE ENHANCED BY MANY ORDERS OF MAGNITUDE BY POST-TRANSCRIPTIONAL REGULATION SUCH AS ALTERNATIVE SPLICING AND MODIFICATION AND DEGRADATION OF MRNA, WHICH IN TURN LEADS TO A GREATER PROTEIN DIVERSITY AND THUS A GREATER FUNCTIONAL COMPLEXITY OF THE CELL. THIS SEEMS PARTICULARLY RELEVANT IN THE CONTEXT OF COMPLEX PROCESSES SUCH AS CELL SPECIFICATION AND ORGANOGENESIS. THE IMPORTANCE OF RNA REGULATION IS FURTHER SUPPORTED BY THE LARGE NUMBER RNA-BINDING PROTEINS ENCODED IN THE HUMAN GENOME (~1,500) AND THEIR EVER MORE PROMINENT EMERGENCE IN THE CONTEXT OF DISEASE. DESPITE THE CLEAR EVIDENCE OF THE RELEVANCE OF RNA REGULATION, MUCH LESS REMAINS KNOWN COMPARED TO THE EXCEPTIONALLY WELL-RESEARCHED GENE REGULATORY MECHANISMS. THIS LACK OF PROGRESS IS IN PART DUE TO TECHNICAL CHALLENGES ASSOCIATED WITH STUDYING AND MANIPULATING RNA, PARTICULARLY DURING EARLY DEVELOPMENT. HOWEVER, RECENT ADVANCEMENTS IN THIS AREA NOW AFFORD NEW OPPORTUNITIES TO BROADEN OUR KNOWLEDGE IN THESE CRITICAL REGULATORY MECHANISMS AND START TO FILL THIS CRITICAL KNOWLEDGE GAP. HERE WE WILL INTERROGATE RNA-BINDING PROTEINS IMPORTANT FOR CARDIAC DEVELOPMENT, SPECIFICALLY THE THE X-LINKED PROTEIN DDX3X. MUTATIONS IN DDX3X LEAD TO DDX3X SYNDROME, WHICH IS CHARACTERIZED BY INTELLECTUAL DISABILITY, AUTISM SPECTRUM DISORDER, CONGENITAL BRAIN MALFORMATIONS AND MOTOR PROBLEMS. DDX3X HAS NOT BEEN INTERROGATED DURING CARDIOGENESIS TO DATE, BUT RECENT STUDIES HAVE UNCOVERED THAT INDIVIDUALS WITH DDX3X SYNDROME FREQUENTLY PRESENT WITH CONGENITAL HEART DISEASE. BASED ON OUR PRELIMINARY FINDINGS WE HYPOTHESIZE THAT DDX3X ACTS IN A SPATIO-TEMPORAL MANNER, BY TARGETING DISTINCT REGULATORY NETWORKS DURING THE DEVELOPMENT OF THE DIFFERENT CELL TYPES OF THE HEART. WE FURTHER HYPOTHESIZE THAT DISEASE-CAUSING MUTATIONS IN DDX3X AFFECT CELLULAR DYSFUNCTION BY SPECIFIC MECHANISMS OF DDX3X TARGET REGULATION. AIM 1 WILL UNCOVER THE DIRECT, AND FUNCTIONALLY RELEVANT TARGETS OF DDX3X. AIM 2 WILL DETERMINE THE CELLULAR PHENOTYPE OF DDX3X-DEFICIENT MALE AND FEMALE EMBRYOS. AIM 3 WILL ELUCIDATE GENOTYPE-PHENOTYPE CORRELATIONS IN DDX3X SYNDROME PATIENT-DERIVED HPSC-CMS. SUCCESSFUL COMPLETION OF THE AIMS ARE EXPECTED TO IDENTIFY AND CHARACTERIZE THE CELLULAR REQUIREMENTS AND IN DEPTH MOLECULAR MECHANISMS OF DDX3X, A NEW RNA-BINDING PROTEIN THAT WE FOUND TO BE ESSENTIAL FOR HEART DEVELOPMENT. THE OVERALL AND LONG-TERM GOAL IS TO CONTRIBUTE TO A BETTER UNDERSTANDING OF RNA REGULATORY MECHANISMS, SPECIFICALLY DURING CARDIAC DEVELOPMENT AND IN THE CONTEXT OF THE FORMATION OF CONGENITAL HEART DISEASE.

Posted 6/21/24, 12:00 AM